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Abstract
Background: Myelination of peripheral nerves by Schwann cells requires not only the Egr2/Krox-
20 transactivator, but also the NGFI-A/Egr-binding (NAB) corepressors, which modulate activity
of Egr2. Previous work has shown that axon-dependent expression of Egr2 is mediated by
neuregulin stimulation, and NAB corepressors are co-regulated with Egr2 expression in peripheral
nerve development. NAB corepressors have also been implicated in macrophage development,
cardiac hypertrophy, prostate carcinogenesis, and feedback regulation involved in hindbrain
development.
Results: To test the mechanism of NAB regulation in Schwann cells, transfection assays revealed
that both Nab1 and Nab2 promoters are activated by Egr2 expression. Furthermore, direct binding
of Egr2 at these promoters was demonstrated in vivo by chromatin immunoprecipitation analysis
of myelinating sciatic nerve, and binding of Egr2 to the Nab2 promoter was stimulated by neuregulin
in primary Schwann cells. Although Egr2 expression activates the Nab2 promoter more highly than
Nab1, we surprisingly found that only Nab1 – but not Nab2 – expression levels were reduced in
sciatic nerve from Egr2 null mice. Analysis of the Nab2 promoter showed that it is also activated
by ETS proteins (Ets2 and Etv1/ER81) and is bound by Ets2 in vivo.
Conclusion: Overall, these results indicate that induction of Nab2 expression in Schwann cells
involves not only Egr2, but also ETS proteins that are activated by neuregulin stimulation. Although
Nab1 and Nab2 play partially redundant roles, regulation of Nab2 expression by ETS factors
explains several observations regarding regulation of NAB genes. Finally, these data suggest that
NAB proteins are not only feedback inhibitors of Egr2, but rather that co-induction of Egr2 and
NAB genes is involved in forming an Egr2/NAB complex that is crucial for regulation of gene
expression.
Background
Members of the EGR (early growth response) family of
transactivators fulfill critical roles in diverse systems,
including nervous system development, bone formation,
and fertility. Transcriptional activity of three EGR family
members (Egr1/NGFI-A, Egr2/Krox20, and Egr3) is regu-
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lated by interaction with the NAB (NGFI-A/EGR binding)
family of transcriptional corepressors. The Nab1 protein
was first identified by screening a yeast two-hybrid library
for proteins that interact with a repressive domain within
Egr1[1], and Nab2 was subsequently found to share simi-
lar properties [2]. Both Nab1 and Nab2 can bind to a con-
served domain in Egr1, Egr2 and Egr3. NAB proteins
repress activation of several EGR target promoters [3-5],
and the repression mechanism involves interaction with
the CHD4 subunit of the Nucleosome Remodeling and
Deacetylase (NuRD) complex [6].
The most severe phenotypes caused by loss of EGR func-
tion have been found in mice lacking the Egr2/Krox20
gene (hereafter referred to as Egr2). Characterization of
these mice revealed three principal defects: 1) defective
hindbrain segmentation with the loss of rhombomeres r3
and r5 [7,8], 2) defective bone formation [9], and 3) fail-
ure of Schwann cells to myelinate peripheral nerves [10-
12]. Target genes regulated by Egr2 in Schwann cells
include myelin genes such as Myelin Protein Zero and
Myelin-associated glycoprotein [10-15]. As a conse-
quence, most mice with a homozygous Egr2 disruption
die shortly after birth, although mice that are
homozygous for a hypomorphic Egr2 allele survive some-
what longer [11].
Because of the myelination defect in peripheral nerves of
Egr2 knockout mice, several groups have screened human
patients with peripheral neuropathies for mutations in
the EGR2 gene. Mutations in EGR2 have been identified
in several patients with myelin disorders, such as Charcot-
Marie-Tooth (CMT) disease, Dejerine-Sottas Syndrome,
and Congenital Hypomyelinating Neuropathy [16-20].
Most of the neuropathy-associated mutations occur
within the zinc fingers of EGR2 and prevent DNA-binding
[21]. However, one of the EGR2 mutations associated
with a very severe congenital hypomyelinating neuropa-
thy [I268N, [16]] prevents binding of EGR2 to NAB core-
pressors [21]. The importance of NAB corepressors to the
regulation of peripheral nerve myelination by Egr2 was
recently confirmed by the demonstration that a double
knockout of the Nab1/Nab2 genes results in a phenotype
very similar to that of the Egr2 knockout: early lethality
and peripheral neuropathy resulting from arrested myeli-
nation [22]. Moreover, NAB genes have been implicated
in several other physiological processes, including macro-
phage development, cardiac hypertrophy, prostate car-
cinogenesis, and feedback regulation involved in
hindbrain development [23-26].
As critical regulators of peripheral myelination, it is
important to probe the mechanism of NAB regulation.
Recent work has shown that Nab1 and Nab2 are induced
by neuregulin signaling [22]. Neuregulin signaling plays
an extremely important role in axon-derived signals for
Schwann cell myelination [27-35]. Moreover, Egr2 and
NAB expression appear to be closely linked, as Nab1 and
Nab2 are co-regulated with Egr2 after nerve crush injury,
and both corepressors are induced by ectopic Egr2 expres-
sion in cultured Schwann cells [22,36,37]. However,
direct regulation of Nab1 and Nab2 by Egr2 has not been
demonstrated in vivo. The following data demonstrate
direct regulation of NAB expression by Egr2 in myelinat-
ing sciatic nerve, and indicate that other neuregulin-regu-
lated pathways are specifically involved in inducing Nab2
expression.
Results
Induction of Nab promoters by Egr2
Sequence analysis of the Nab1 and Nab2 promoters iden-
tified several conserved motifs that resemble Egr2 binding
sites [22]. To test whether these sites bind Egr2, the mouse
Nab1 and Nab2 promoters were analyzed by DNase I foot-
printing. In the presence of recombinant Egr2, there were
strongly protected regions encompassing three previously
identified sites in the Nab2 promoter, as well as some
weaker protections (Figure 1A). Interestingly, previous
analysis of Egr2 site specificity indicated a strong prefer-
ence for T in the 4th position of the consensus sequence
[GCGTGGGCG, [38]], and each of the three strongly pro-
tected sites have a T in the 4th base. A similar analysis of
the mouse Nab1 promoter (Figure 1B) confirmed binding
of Egr2 to the conserved binding sites identified previ-
ously [22]. The strong binding site at the 3' end of the
mouse Nab2 promoter corresponds to a site of phorbol
ester-induced Egr1 binding in a recent analysis of the
human  NAB2  promoter using electrophoretic mobility
shift assays [39].
To test the function of the Egr2 binding sites, fragments
encompassing the conserved regions of the Nab1  and
Nab2 promoters were fused to a luciferase reporter gene
and transfected into JEG-3 cells, which exhibit a low level
of expression of EGR proteins [40]. As shown in Figure
1C, expression of Egr2 activated the Nab1 promoter up to
15-fold, and the Nab2 reporter was increased 25-fold. Two
of the Egr2 binding sites in the Nab2  promoter were
mutated to determine how that would affect activation by
Egr2. As shown in Figure 1, we still observed some resid-
ual activation of the promoter, but the induction was
much less than observed with the wild type promoter. Pre-
vious work had indicated that Nab2 is more inducible by
serum and neuregulin than Nab1 [2,22]. Moreover, the
Nab2 promoter was more highly induced by Egr2 in the
transfection experiments. However, this disparity is some-
what surprising, given that the Nab1 promoter contains
more Egr2 binding sites than does Nab2.BMC Molecular Biology 2007, 8:117 http://www.biomedcentral.com/1471-2199/8/117
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Egr2 activates the Nab1 and Nab2 promoters Figure 1
Egr2 activates the Nab1 and Nab2 promoters. A) The plot shows percent identity of the human and mouse Nab2 loci upstream of the first exon. 
DNase I footprinting analysis of a 1000 bp fragment of the mouse Nab2 promoter in the presence of recombinant Egr2 protein revealed two footprinted 
regions (solid line) with some weaker protections (dotted lines). The footprinted regions correspond to three of the four previously identified conserved 
sites [filled circles, 22] that conform to the Egr2 consensus binding site. There was no apparent footprint over putative site #4 identified in previous 
sequence analysis of the Nab2 promoter [22] M = marker lane. B) A similar analysis of the mouse Nab1 promoter confirmed binding of Egr2 to the six pre-
viously identified conserved binding sites in the mouse Nab1 promoter [filled circles, 22]. C) JEG-3 cells were transfected with a luciferase reporter plas-
mid containing either the Nab1 or Nab2 promoter, and the indicated amounts of an Egr2 expression construct. The mutant Nab2 promoter contains 
mutations in the two upstream Egr2 binding sites. Egr2 binding sites are indicated by filled circles. The y-axis shows the fold activation normalized to the 
activity of the reporter alone. Means and standard deviations of three separate transfections are shown. Activation of both Nab1 and Nab2 promoters by 
25 ng Egr2 (compared to control) was statistically significant (P =< 0.002).BMC Molecular Biology 2007, 8:117 http://www.biomedcentral.com/1471-2199/8/117
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Neuregulin stimulation increases Egr2 occupancy of the 
Nab1 and Nab2 promoters
In rat Schwann cells treated with neuregulin, there is a
large induction of Egr2 (within 1 hour), followed by a
delayed induction of Nab1 and Nab2, which peaks at two
hours after neuregulin addition [22], with Nab2  being
more highly induced than Nab1. To test if neuregulin
stimulates direct binding of Egr2 to the NAB promoters,
chromatin immunoprecipitation (ChIP) assays were used,
in which formaldehyde is used to covalently crosslink
DNA with any associated proteins and the proteins of
interest are subsequently immunoprecipitated [14,41].
Primary rat Schwann cells were treated for 2 hours with
neuregulin and then cross-linked with 1% formaldehyde.
Sonicated chromatin was then immunoprecipitated with
an Egr2 antibody or control IgG. An untreated culture of
Schwann cells was also cross-linked and immunoprecipi-
tated similarly. After crosslinks were reversed, purified
DNA was analyzed by quantitative PCR using primer sets
proximal to the Egr2 binding sites in the Nab1 and Nab2
promoters. As shown in Figure 2, binding of Egr2 to the
Nab1 and Nab2 promoters was significantly stimulated
upon treatment with neuregulin. Egr2 binding was not
detected at an immunoglobulin promoter [IMG2A, which
lacks Egr2 binding sites and is transcriptionally silent in
Schwann cells, [14,41]] in either sample. Evidence for the
specificity of the antibody used for ChIP analysis includes
induction of Egr2 binding by neuregulin (Figure 2), and
immunoblot analysis using this antibody reveals a band
of the correct size (Figure 3). In addition, this antibody
has been extensively tested with multiple negative control
sites [6,14,41], and expression of dominant negative Egr2
(consisting of the DNA-binding domain of Egr2) reduces
Egr2 binding in this assay (unpublished data). In parallel
cultures, Nab2 mRNA was induced 11-fold upon treat-
ment with neuregulin for 2 hours, consistent with previ-
ously published results [22].
Egr2 binds to the Nab1 and Nab2 promoters in 
myelinating sciatic nerve
We have recently employed ChIP analysis of myelinating
sciatic nerve to test whether Egr2 directly regulates specific
elements in vivo [6,14,41]. Egr2 expression increases con-
currently with initiation of myelination in rat sciatic nerve
within two weeks after birth [42], which is also observed
in immunoblot analysis of Egr2 expression in P5 and P15
rat sciatic nerve (Figure 3). Therefore, freshly dissected sci-
atic nerves from rat pups at P10 (from pools of 5–13
pups) were minced in 1% formaldehyde after dissection.
After immunoprecipitation of sonicated chromatin, quan-
titation of the ChIP assays demonstrated significant
enrichment of Egr2 at both Nab1 and Nab2 promoters in
rat sciatic nerve (Figure 3).
Nab expression levels in peripheral nerve of Egr2-deficient 
mice
To independently test the regulation of NAB genes by Egr2
in vivo, we examined NAB expression levels in the Egr2/
Krox20 knockout (Figure 4). In these mice, Schwann cells
develop normally and associate with axons, but fail to ini-
tiate myelination of peripheral nerves [10]. The sciatic
nerves of seventeen wild type and knockout animals at P7
were pooled, and the levels of Nab1 and Nab2 were deter-
mined by quantitative PCR. Previous analysis of these
samples had indicated that expression of many myelin-
associated Egr2 target genes are significantly reduced in
the knockout nerves [14,41,43]. Consistent with the data
from the transfection and ChIP assays, we observed a sig-
nificant decrease in the expression of Nab1. A similar
reduction in Nab1 expression was reported in mice with a
hypomorphic allele of Egr2 [22]. In contrast, the expres-
sion level of Nab2 was not significantly different in mice
containing the null allele of Egr2/Krox20.
Neuregulin stimulates Egr2 binding to the Nab2 promoter in  primary Schwann cells Figure 2
Neuregulin stimulates Egr2 binding to the Nab2 promoter in pri-
mary Schwann cells. Primary rat Schwann cells, untreated or exposed 
to neuregulin for 2 h, were analyzed by ChIP assay. Formaldehyde-
crosslinked chromatin from the two cultures were immunoprecipitated 
with an antibody for Egr2 (filled bars) or purified control IgG (open bars). 
Percentage recovery relative to input was determined using quantitative 
PCR with primers designed for the Nab1, Nab2 and Immunoglobin 2A 
(IMG2A) promoters. The horizontal lines above the promoter diagrams 
indicate the positions of the amplicons derived from the primer sets used 
for ChIP analysis. Means and standard deviations were calculated for dupli-
cate measurements from two independent experiments.
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Regulation of the Nab2 promoter by ETS proteins
Given the unexpected finding that the expression level of
Nab2 was not lower in the absence of Egr2, the Nab2 pro-
moter was screened for other transcription factor binding
sites that could contribute to Nab2 expression, thereby
compensating for the loss of Egr2 activation. Analysis of
the Nab2 promoter revealed several putative binding sites
for ETS transcription factors (diagrammed in Figure 6B).
Interestingly, ETS proteins are regulated by neuregulin sig-
naling [44-46]. In addition, previous studies have identi-
fied ETS transcription factors as playing an important role
in autocrine and neuregulin-mediated survival of
Schwann cells, and showed that several ETS genes, includ-
ing Net/Elk3, Ets2, GABPα and Etv1/ER81, are expressed
in E12 and newborn mouse peripheral nerve [47]. Ets2
and Etv1/ER81 (hereafter referred to as Etv1) were
selected for further analysis as they were highly expressed
in microarray analyses of mouse sciatic nerve [see 94246,
92927 probe sets in supplementary data of [48,49]].
Quantitative PCR analysis confirmed significant levels of
Ets2  and  Etv1  in mouse and rat sciatic nerves during
peripheral nerve myelination (data not shown), and
Western analysis (Figure 5A) showed that both Ets2 and
Etv1 are developmentally increased in rat sciatic nerve at
P15, compared to the P5 (early myelination) timepoint.
Since Nab2 expression was unaffected in the Egr2 knock-
out, we assessed the expression levels of Ets2, Etv1, and
Elk3 in Egr2 knockout nerves from P7 mice. Interestingly,
Ets1 expression was previously shown to be elevated in
sciatic nerve of Egr2-deficient mice [11], and Etv1 expres-
sion was somewhat higher in the Egr2 null mice as com-
pared to wild-type mice (Figure 5B). The presence of Ets2
and Etv1 in mouse and rat sciatic nerve during myelina-
tion [47-49], as well as in Egr2 null mice, suggest that ETS
transcription factors could compensate in the absence of
Egr2 to maintain Nab2 expression levels.
ETS proteins activate the Nab2 promoter
To test whether ETS proteins activate the Nab1 and Nab2
promoters, JEG3 cells were transfected with the Nab1 or
Nab2  reporters described above, along with expression
vectors for Ets2 and Etv1. Western analysis revealed that
Ets2 and Etv1 expression in JEG3 cells is much lower than
found in the S16Y Schwann cell line (Figure 6A). The
Expression levels of Nab genes in Egr2 null mice Figure 4
Expression levels of Nab genes in Egr2 null mice. Sciatic 
nerves were isolated from Egr2 wild type (+/+) and knockout (-/-) 
mice. The relative levels of the Nab1 and Nab2 genes are indicated 
relative to the wild type sample, which was set as 1. Each level was 
determined from >10 pooled mice of the same genotype and nor-
malized to the level of 18S rRNA. Quantitative PCR assays were 
performed in duplicate, and the standard deviation is indicated. 
Further analysis of nerves from individual mice at P7 (3 of each 
genotype) confirmed reduction of Nab1 (expression level of 0.58 
for Egr2 -/- relative to 1 for wild type, P = 0.04). Expression level 
of Nab2 in the same samples was 0.95 relative to wild type.
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Egr2 binds NAB promoters in myelinating sciatic nerve Figure 3
Egr2 binds NAB promoters in myelinating sciatic nerve. Formal-
dehyde-crosslinked chromatin from sciatic nerves of rats at P10 was 
immunoprecipitated with an antibody for Egr2 (filled bars) or purified con-
trol IgG (open bars). Percentage recovery relative to input DNA was 
determined by quantitative PCR with the same primers used in Figure 2. 
The horizontal lines above the promoter diagrams indicate the positions 
of the amplicons derived from the primer sets used for ChIP analysis. 
Binding at the transcriptionally silent IMG2A locus was analyzed as a nega-
tive control. The data are representative of at least two independent 
experiments; average fold enrichment for Egr2 binding (relative to control 
IgG immunoprecipitation) to the Nab2 promoter in four independent 
experiments was 51-fold (P = 0.016). Inset: Immunoblot analysis with the 
same antibody used in the ChIP assay was used to detect Egr2 (~70 kD) in 
rat sciatic nerve lysates at P5 and P15. Three amounts of the P15 lysate (in 
increasing 2-fold amounts in lanes 2–4) were loaded to facilitate compari-
son with the expression level at P5. The blot was reprobed with a β-actin 
antibody as a normalization control (bottom panel).
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Nab2 promoter was significantly induced by Ets2 and Etv1
expression, and this induction was further potentiated by
coexpression of Egr2 (Figure 6B). A dominant-negative
ETS construct [consisting of the DNA-binding domain of
Ets1, as used previously, [47]] specifically interfered with
ETS-mediated induction of the promoter and had no
effect on activation by Egr2 (data not shown). In contrast,
the Nab1 promoter was activated to a lower extent by Ets2
and Etv1, and the ETS factors did not appear to augment
activation of the Nab1 promoter by Egr2.
We tested the ability of Ets2 and Etv1 to induce a mutated
version of the Nab2 promoter construct containing muta-
tions in two of the Egr2 binding sites (Figure 6C). As
observed previously, the mutant promoter is only weakly
induced by Egr2. However, Ets2 and Etv1 were nonethe-
less able to induce this mutant reporter in the absence of
Egr2, although the synergistic activation observed with
Egr2 was clearly diminished in the mutant promoter.
Ets2 binds to the Nab2 promoter in S16Y Schwann cells
In order to test if ETS factors directly regulate Nab2 in
Schwann cells, we carried out ChIP assays in the S16Y
Schwann cell line [50], which expresses significant levels
of Nab1, Nab2 (data not shown) and ETS factors (Figure
5A). S16Y cells were crosslinked in 1% formaldehyde and
sonicated chromatin was immunoprecipitated with either
an affinity purified Ets2 antibody (used previously for
ChIP analysis, [51]) or an IgG control antibody. Quanti-
tative PCR was carried out on purified DNA with primer
sets in the Nab1 and Nab2 promoters, and the IMG2A
locus as a negative control. As shown in Figure 7, we
observed significant enrichment of Ets2 using two primer
sets in the Nab2 promoter, whereas binding of Ets2 was
not detected at either the Nab1 promoter or the IMG2A
negative control locus. A similar trend in Ets2 occupancy
was observed in the S16 Schwann cell line ([50], data not
shown).
One limitation of the ChIP assay is that it cannot be used
to precisely localize binding of transcription factors. How-
ever, the analysis suggests that Ets2 binding is separable
from Egr2, because Ets2 binding was not detected using
the primer set (#3) that was used previously to detect
binding of Egr2 within the Nab2 promoter (Figures 2 and
3). In addition, the relatively simple recognition site of
ETS factors (GGAA or GGAT) does not make sequence
analysis necessarily predictive, since the upstream cluster
of putative ETS binding sites (spanned by primer set 1)
does not appear to bind Ets2. Accordingly, deletion of the
upstream cluster of putative ETS binding sites does not
affect activation of the Nab2  promoter in transfection
assays (data not shown). Ets2 binding appears to occur in
two separable regions of the Nab2 promoter, as detected
by primer sets 2 and 4. Interestingly, primer set 4 overlaps
with the corresponding segment of the human NAB2 pro-
moter that was recently shown to be inducible by phorbol
ester [39], which also activates ETS proteins. Overall, these
data are consistent with regulation of the Nab2 promoter
by ETS transactivators in vivo.
Discussion
Recent studies have shown that NAB proteins are required
for peripheral nerve myelination by Schwann cells, as
mice lacking Nab1/Nab2  displayed a severe congenital
hypomyelinating phenotype similar to Egr2  knockout
mice [22]. The molecular roles of Egr2 and NAB proteins
appear to be closely intertwined at several levels, includ-
ing both physical interaction and coregulation [2,21-24].
Several previous studies have suggested that EGR factors
regulate the expression of Nab1 and Nab2 corepressors.
First, Nab2 and, to a lesser extent, Nab1 are activated in a
delayed early fashion by a variety of stimuli that induce
expression of EGR family members [2,23,39,52,53]. For
example, neuregulin treatment of Schwann cells stimu-
lates Egr2 and activates Nab1 and Nab2 expression in a
slightly delayed manner [22]. Second, the Nab2 promoter
can be activated by EGR factors in transient transfection
studies [[39], Figure 1, [54]], and ectopic expression of
Egr1 and Egr2 stimulates expression of endogenous Nab1
and Nab2 in a variety of cell lines, including Schwann cells
[22,36,37,55,56].
ETS expression in peripheral nerve Figure 5
ETS expression in peripheral nerve. A) Immunoblot analysis was used 
to determine protein levels of Etv1 and Ets2 in rat sciatic nerve at P5 and 
P15. Three amounts of the P15 lysate (in increasing 2-fold amounts) were 
loaded to facilitate comparison with the expression level at P5. For each 
antibody, the blot was reprobed with a β-actin antibody as a normalization 
control. B) Expression levels of Ets2, Etv1, and Elk3, in wild-type (+/+) and 
homozygous null (-/-) Egr2 mice at P7, were determined by quantitative 
RT-PCR. The relative levels of each gene were normalized to 18S rRNA 
and fold induction was determined as compared to wild-type sample, 
which was set as 1.
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These earlier studies, however, did not test direct regula-
tion of NAB corepressors by Egr2. Our data provide sev-
eral lines of evidence to establish Nab2 regulation by Egr2
in vivo. First, DNAse footprinting analysis identified sev-
eral Egr2 protected sites in both Nab1 and Nab2 promot-
ers. Second, activation of Nab2  b y  E g r 2  i n  t r a n s i e n t
transfection assays was severely compromised when Egr2
binding sites were mutated (Figure 1). Finally, ChIP assays
demonstrated direct binding of Egr2 to both promoters in
cultured Schwann cells as well as myelinating sciatic nerve
(Figures 2 and 3). Several studies have implicated neureg-
ulin signaling as a critical factor in Schwann cell survival
and stimulation of myelination [27-34]. Egr2 occupancy
at both Nab1 and Nab2 was significantly enhanced upon
neuregulin stimulation of Schwann cells. Our results pro-
vide the first demonstration of neuregulin-induced bind-
ing of a transcription factor to a specific promoter in
Schwann cells.
Several groups have shown that Type III neuregulin
(membrane-bound) plays a central role in regulating
myelination in vivo [29,30,35]. Therefore, addition of sol-
uble neuregulin (as in Figure 2) does not act as a mimic of
myelination. Nonetheless, Egr2 is regulated by both solu-
ble neuregulin and interaction with Type III neuregulin
[22,57,58], and therefore soluble neuregulin probably
induces some of the early pathways relating to Egr2 induc-
tion in vivo. Since Egr2 expression is regulated by Type III
neuregulin signaling in vivo [58], our ChIP data in myeli-
ETS activation of NAB promoters Figure 6
ETS activation of NAB promoters. A) Lysates of the JEG3 and S16Y (Schwann cell) lines were probed with the antibodies directed against Etv1 and 
Ets2, and respective blots were re-probed with β-actin antibody as a loading control. B) JEG3 cells were transfected with either the pGL3-Nab2 or pGL3-
Nab1 reporter. Ets2 (25 ng), Etv1 (50 ng), or Egr2 (25 ng) expression plasmids were co-transfected as indicated in each panel. The y-axis shows the fold 
activation normalized to the activity of the reporter alone. Means and standard deviations of three separate transfections are shown. Average fold induc-
tion of the NAB2 promoter by Ets2 and Etv1 in 8 independent transfections was 19.5- and 7.3-fold, respectively (P =< 10-6 for both). C) Similar transfec-
tions were performed to compare ETS activation of the pGL3-Nab2 (wild type) promoter with the mutant Nab2 reporter construct in which two Egr2 
binding sites are mutated (used in Figure 1c). The diagram indicates potential ETS binding sites identified by sequence analysis relative to the footprinted 
Egr2 binding sites in the Nab2 promoter.
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nating rat sciatic nerve presumably reflect type III neureg-
ulin-dependent binding of Egr2 to the NAB promoters.
Previous work showed that expression of Nab1 and Nab2
in zebrafish hindbrain is dependent on Egr2 expression
[26]. Therefore, it was surprising that Nab2 levels were not
affected in Egr2 knockout mice. In contrast, Nab1 levels
were significantly lower in the absence of Egr2, even
though the Nab1 promoter is less effectively activated by
neuregulin and Egr2  expression (Figure 1, [22]). These
data suggested that Nab2 might be coregulated by other
factors that compensate for loss of Egr2, and promoter
analysis revealed several conserved binding sites for ETS
transcription factors. ETS family members are activated by
neuregulin signaling [45-47]. Since Nab2 is more highly
induced by neuregulin stimulation [22], we tested
whether ETS proteins are involved in regulation of Nab2.
Both Ets2 and Etv1 activated the Nab2 promoter in trans-
fection assays, and we observed a cooperative effect on the
Nab2 promoter when Egr2 was co-expressed together with
Ets2 or Etv1. Furthermore, chromatin immunoprecipita-
tion analysis with an Ets2 antibody detected binding in
the Nab2 promoter, but not in the Nab1 promoter. Unfor-
tunately, we have been unable to find an Etv1 antibody
that is suitable for ChIP analysis, but recent immunohis-
tochemical studies indicate that Etv1/ER81 is expressed in
Schwann cells [59]. Based on our data, we propose that
the higher induction of Nab2 by neuregulin, compared to
Nab1 [22], is due to synergistic activation of the Nab2 pro-
moter by Egr2 and ETS factors. Consequently, the main-
tained expression of Nab2 levels in the knockout could be
mediated by elevated levels of Etv1 (Figure 5), Ets1 [11],
or other ETS factors that may be revealed by a more com-
prehensive analysis of family member expression. In addi-
tion, although Ets2  mRNA is not induced in the Egr2
knockout, its activity (as well as that of other ETS factors)
could be elevated post-transcriptionally (e.g. phosphor-
ylation).
In contrast, the Nab1 promoter was more modestly acti-
vated by ETS proteins, suggesting that Nab1 is more exclu-
sively dependent on EGR factors and consequently is
more reduced in the absence of Egr2. However, the mod-
est induction of the Nab1  promoter by ETS factors in
transfection assays could reflect some level of regulation
of Nab1 expression by ETS proteins in Schwann cells, par-
ticularly if there are other ETS binding sites that lie outside
of the Nab1 promoter regions we have analyzed. A limita-
tion of these studies is that the importance of the NAB
promoters relative to more remote enhancer elements has
not been established. The mechanism of Nab2 activation
by ETS remains to be determined, since only potential ETS
binding sites in the Nab2 promoter have been identified.
Despite the commonality of the core ETS motif (GGAa/t),
individual ETS factors have distinct binding site prefer-
ences. Therefore, future studies will focus on identifying
the relevant ETS factor(s) using RNAi approaches and/or
knockout mice in order to facilitate such a mechanistic
analysis.
Given the in vivo evidence that ETS proteins regulate
expression of Egr1 and Egr2 [23,60-62], it seems likely
that co-induction of Egr2 and Nab2 by ETS transcription
factor activation may have evolved to ensure formation of
sufficient Egr2/NAB complexes that are required for spe-
cific gene regulation events in Schwann cell differentia-
tion. This may also prevent inappropriate activation of
some target genes if Nab2 was not immediately present at
the onset of Egr2 induction. Alternatively, it is possible
that Nab2 modulates other transcription factors, so that
its induction should not exclusively depend on Egr2.
Several groups have proposed that the induction of Nab2
constitutes a negative feedback loop in which EGR activa-
tors induce expression of their own corepressor
[2,26,39,53]. Our studies refine this model by showing
that other neuregulin-regulated pathways direct Nab2
expression. In addition, recent publications have shown
that Egr2 is required for certain gene repression mecha-
nisms during myelination [11,12]. Therefore, we suggest
that the induction of NAB proteins does not merely con-
Ets2 binds to the endogenous Nab2 promoter Figure 7
Ets2 binds to the endogenous Nab2 promoter. Cross-linked chro-
matin from the S16Y Schwann cell line was immunoprecipitated with Ets2 
antibody (filled bars) or purified control IgG (open bars). Percentage 
recovery relative to input DNA was determined for IMG2A, Nab1, and 
several Nab2 primer sets as indicated in the diagram. Potential ETS binding 
sites identified by sequence analysis are shown as filled rectangles. Primer 
set 3 was used in previous figures to detect Egr2 binding.
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stitute a negative feedback loop, but rather, that co-induc-
tion of Egr2 and NAB proteins by axon-dependent signals
(e.g. neuregulin/erbB) is required to form an Egr2/NAB
complex that actively represses transcription of specific
genes during peripheral nerve myelination (Figure 8).
These results are consistent with our demonstration of
direct repression of the Rad gene by an Egr2/NAB complex
in Schwann cells [6,22], as well as recent publications
implicating repression by the Egr2/NAB complex in mac-
rophages and cardiomyocytes [23,63].
Our studies do not rule out the possibility that other EGR
family members and/or other zinc finger proteins may
partially compensate in maintaining Nab2 levels in the
absence of Egr2. Indeed, previous work has shown that
Egr1 and Egr2/Krox20 are coexpressed in Schwann cells at
the onset of myelination (P1). In contrast by one month
of age, Egr2 is exclusively expressed in myelinating
Schwann cells, whereas Egr1 is confined to nonmyelinat-
ing Schwann cells [64]. Egr1 is induced ~2-fold in sciatic
nerve of mice homozygous for a hypomorphic Egr2 allele
[11], and our analysis indicates that Egr1  mRNA is
induced about 1.5-fold in the complete absence of Egr2
(data not shown). Importantly, compensation by other
Egr family members is not sufficient to maintain Nab1
levels despite the presence of several Egr1 binding sites,
and fails to maintain expression of other Egr2 target genes
like myelin protein zero, which is reduced up to 50-fold
in the Krox20/Egr2 knockout [10-14], suggesting that non-
EGR factors contribute significantly to regulation of Nab2
expression. Interestingly, regulation of NAB expression by
Egr2 is consistent with previous observations that Nab1
and  Nab2  are co-regulated with Egr2  after nerve crush
injury [22,36]. However, the decrease in Nab2 expression
following nerve injury would be consistent not only with
regulation by Egr2, but also by loss of neuregulin-depend-
ent (i.e. axon-dependent) induction of ETS factors, analo-
gous to regulation of ETS factors by neuregulin signaling
observed in other systems [44-46].
The involvement of ETS transcription factors in Nab2 reg-
ulation resolves several puzzling observations regarding
Nab1 and Nab2 activation. First, Nab2 expression is more
responsive than Nab1 to several stimuli including serum,
neuregulin and NGF [2,22], even though the Nab1 pro-
moter contains more EGR binding sites than Nab2. Sec-
ond, Nab2 expression is already fairly elevated by E17 in
profiling studies of peripheral nerve myelination, even
though Egr2 levels do not peak until P10 [49]. Finally, a
recent analysis of hematopoietic development showed
that expression of the ETS factor, PU.1, induced expres-
sion of both Egr2 and Nab2, and the induction of Nab2
was shown to be Egr2-independent [23]. Our analysis of
the Nab2 promoter provides a mechanism for Egr2-inde-
pendent activation of Nab2 by ETS proteins.
Conclusion
Our results demonstrate that Egr2 is directly involved in
regulation of both NAB1 and NAB2 corepressors, indicat-
ing that axon-dependent induction of NAB expression is
partially dependent on Egr2. However, the maintained
expression of Nab2 in Egr2 deficient mice suggested that
other factors could compensate for lack of Egr2. Transfec-
tion experiments and chromatin immunoprecipitation
assays indicated that Ets2 and Etv1 specifically activate the
Nab2 promoter, but not Nab1, which provides an explana-
tion for the differential regulation of NAB corepressors in
several developmental systems. Finally, these results sug-
gest that NAB corepressors are not simply feedback inhib-
itors, but that co-induction of Egr2 with NAB corepressors
is critically involved in forming a transcriptional complex
required for gene regulation events.
Methods
Promoter Analysis
Putative Egr2 binding sites were identified by comparison
to the previously defined consensus Egr2 binding site
[38], and sequence analysis for potential binding sites was
performed using the rVISTA program [65]. Footprinting
was carried out by incubating 200 ng of purified, FAM-
labeled promoter fragments in the presence or absence of
recombinant Egr2 protein, and 500 ng of a non-specific
20 bp oligonucleotide in binding buffer (20% glycerol, 20
mM Tris 7.5, 50 mM KCl, 5 mM MgCl2, 0.01 mM ZnCl2,
Model for regulation of NAB expression Figure 8
Model for regulation of NAB expression. The figure indicates a 
model for regulation of NAB proteins during myelination, based on the 
requirement of NAB proteins for peripheral nerve myelination. In the first 
model (A), neuregulin/erbB signaling (and/or other axon-dependent sig-
nals) trigger expression of Egr2/Krox20 in myelinating Schwann cells, and 
the induction of NAB proteins by binding of Egr2/Krox20 acts as a nega-
tive feedback control to limit activation of specific target genes that are 
important for myelination. B) The second model suggests that co-induc-
tion of Egr2 and NAB proteins is mediated by neuregulin-activated expres-
sion of ETS factors. Activation of ETS factors induces sufficient amounts of 
NAB proteins so that an Egr2/NAB complex can actively repress specific 
target genes. It is noted that these two models are not necessarily mutu-
ally exclusive and could apply to different target genes in different tissues.
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1 mM DTT, and 0.2 mM PMSF) in a volume of 10 μl. One
microliter of 1000 U/ml DNAse I (Promega) was added
for 1 min at room temperature before adding 90 μl of
0.5% SDS, 100 mM NaCl, and 10 mM EDTA. The result-
ing fragments were resolved on an ABI Prism 377
Sequencer. Recombinant Egr2 was made by fusing the
mouse  Egr2  sequence with the 6 × His tag in pET30a
(Novagen), and purifying the protein from bacteria using
Ni-NTA agarose (Qiagen) according to the manufacturer's
protocol.
Plasmids
A 370 bp NotI/PvuII fragment of the mouse Nab1 pro-
moter (-250 to +120 relative to the transcription start site)
and a 1000 bp KpnI/SmaI fragment of the mouse Nab2
promoter (-850 to +150) were fused to the luciferase gene
in the pGL3 vector (Promega). The two upstream Egr2
binding sites in the Nab2 promoter were destroyed by
replacing C residues at positions 2 and 8 with G. The Etv1
(ER81) expression plasmid was provided by Ralf
Janknecht. The expression construct for Egr2 has been pre-
viously described [4]. A mouse Ets2 expression plasmid
was provided by Barbara Graves [66].
Cell culture conditions and transfection assays
JEG3 cells (a trophoblast-derived cell line) were trans-
fected as described [43,54]. The average luciferase activity
of each sample was normalized to the β-galactosidase
activity from the transfected lacZ reporter. Unless other-
wise indicated, means and standard deviations of two sep-
arate transfections are shown. The S16Y rat Schwann cell
line [50] was maintained in DMEM (Dulbecco's Modified
Eagle's Medium) supplemented with 10% bovine growth
serum (Hyclone). Primary rat Schwann cells were cultured
as described [43].
Expression analysis
Sciatic nerve cDNA from pooled (or individual) Egr2 wild
type, heterozygous and homozygous littermates at day P7
was provided by Lawrence Wrabetz and analyzed as
described [14,41,43]. Quantitative RT-PCR was per-
formed by monitoring in real-time the increase in fluores-
cence of the SYBR-GREEN dye [67] using the TaqMan
7000 Sequence Detection System (Applied Biosystems).
Relative amounts of each gene between samples were
determined using the Comparative Ct method [68] and
normalized to the relative levels of 18S rRNA.
Chromatin immunoprecipitation (ChIP) assays
All experiments were performed in strict accordance with
experimental protocols approved by the University of
Wisconsin, School of Veterinary Medicine. ChIP analysis
of myelinating rat sciatic nerve at postnatal day 10 was
performed as described [14,41], by mincing pooled sciatic
nerves from 8–13 rat pups in 1% formaldehyde for 25
min. For neuregulin stimulation, primary rat Schwann
cells were washed once in serum-free media and cultured
in N2 medium for 24 hours [36]. The cells were treated
with 20 ng/ml neuregulin-1 β isoform (heregulin-β 1,
R&D Systems) for 2 h prior to cross-linking cells with 1%
formaldehyde. Cross-linked cells were sonicated in a
Biorupter sonicator (Diagenode) for 20 minutes.
For each immunoprecipitation, 300 μg of sonicated chro-
matin (as determined by Bio-Rad protein assay) from
either nerves or cells was combined with Egr2 antibody
(Covance) or rabbit IgG control antibody (Upstate) over-
night at 4°C. 10% of this amount was saved as input.
Chromatin-antibody complexes were collected with 30 μl
protein G sepharose (pre-blocked with herring sperm
DNA and Bovine serum albumin) for 1 hour at 4°C.
Beads were washed with low salt, high salt and lithium
chloride buffers as described [14,41]. Crosslinks were
reversed for 5 h at 65°C in buffer containing 1% SDS, 0.1
M NaHCO3 and 200 mM NaCl and DNA was purified
using QIAquick PCR purification kit (Qiagen). Quantita-
tive PCR was carried out on the purified samples in dupli-
cate with primers specific to regions of interest. Percentage
recovery relative to input DNA was determined using the
Comparative Ct method [68]. ChIP analysis in the S16Y
Schwann cell line [50] was performed similarly with an
affinity purified Ets2 antibody [51].
Primer sets used for ChIP analysis were as follows: IMG2a
[41],
Rat  Nab1: F) GGCTTGGCAGGCAGCAT R) GTCGGAG-
GAGCAGGCTTCT
Rat Nab2 promoter #3 (used in Figures 2, 3, and 6): F)
ATAGCTCGGCCTCGGTCAC
R) GGGACTCAAGAATCGGGCTC, and the following
primer sets used in Figure 6
Nab2  #1: F) CGGACCCCTCTCCAACTTTT, R) GCCAT-
GCCGTTAGTTTGAATG
Nab2  #2: F) GTACGTGCGCGTGTCTTTGTA, R)
AGAGCGCAGTTTCACAACCAC
Nab2 #4: GGGCAGAGGCACAGACAGA, R) CCTCCCTC-
CACGTCTTCTCTC
Immunoblotting analysis
Sciatic nerves were dissected from Sprague-Dawley rat
pups at postnatal day 5 (P5) and day 15 (P15) and
homogenized in buffer containing 300 mM NaCl, 50 mM
Tris pH 7.5, 1% Triton X-100, 10 mM EDTA pH 8.0, 1 μg/
mL of pepstatinA, 1 μg/mL Leupeptin and 0.1 mM phe-BMC Molecular Biology 2007, 8:117 http://www.biomedcentral.com/1471-2199/8/117
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nylmethylsulfonyl fluoride. The lysates were then ana-
lyzed by immunoblotting with Ets2 [51], Egr2 (Covance)
or ETV1/ER81 (Santa Cruz, CA) antibody as indicated in
figures. The membranes were reprobed with β-Actin (JLA-
20, Developmental Studies Hybridoma Bank at University
of Iowa) for loading control. The membranes were probed
with horseradish peroxidase-conjugated anti-rabbit or
anti-mouse secondary antibody (Jackson Laboratories,
Bar Harbor, ME, USA). Luminescence was detected with
West pico or west dura chemiluminescence detection sys-
tem (Pierce, Rockford, IL, USA).
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EGR (early growth response) ChIP (chromatin immuno-
precipitation), IMG2a (immunoglobulin G 2a), CMT
(Charot-Marie Tooth)
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